Planep国内上市了吗？

Hypertension is the most common chronic disease and the main risk factor for cardiovascular and cerebrovascular diseases. Hypertension refers to an increase in systemic arterial blood pressure (systolic blood pressure and/or diastolic blood pressure) as the main feature (systolic blood pressure ≥ 140 mm Hg mm Hg, diastolic blood pressure ≥ 90 mm Hg mm Hg). Clinically, it may be accompanied by functional or organic damage to the heart, brain, kidney and other organs. About 60% of patients with hypertension have a family history. It is currently believed to be caused by polygenic inheritance, and 30% to 50% of patients with hypertension have a genetic background. Eplerenone (Planep) is a new generation selective aldosterone antagonist with the trade name Inspra. Eplerenone (Planep) can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension.   

Eplerenone (Planep), approved in the United States in 2002, has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Eplerenone (Planep) has a protective effect on the liver, heart disease, and kidneys without damaging the organs. It can promote urination without losing potassium. It also has a good antihypertensive effect on simple systolic hypertension and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone (Planep) can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.  

Eplerenone (Planep) is so effective in treating hypertension, so is Eplerenone (Planep) available in China? It is understood that eplerenone (Planep) has not yet been launched in China, and due to the limitation of the patent protection period, it will not be launched in the country for a long time in the future. To purchase eplerenone (Planep), patients need to go abroad to buy it in person, or obtain it through domestic overseas medical service institutions.